Exo-FBS
This product maintains cell growth performance comparable to standard FBS, allowing seamless integration into existing cell culture workflows.
- Interchangeable with standard FBS
-
Use at 10% supplementation in common media such as:
- DMEM
- RPMI
No additional protocol modifications are required.
Exo-FBS supports more robust cell growth health than competitors
Figure 1. Exo-FBS supports superior cell growth compared to a competitor exosome-depleted FBS.
HepG2 cells were cultured in media supplemented with standard FBS (control), Exo-FBS, or a competitor’s exosome-depleted FBS (Company G). Cell performance was evaluated after one and two passages. Results show that Exo-FBS yields a higher number of viable cells, as determined by a CCK-8 viability assay (left panel), and promotes healthier cell morphology (right panel) relative to the competitor product.
Figure 2. Bovine α-CD63 ELISA confirms low exosome content in Exo-FBS.
CD63, a well-established exosome-specific marker, was measured by bovine α-CD63 ELISA in standard FBS and Exo-FBS. Exo-FBS exhibited very low CD63 levels relative to standard FBS, consistent with nanoparticle tracking analysis (NTA) results showing reduced numbers of exosome-sized particles. Equal sample volumes (50 µL) of standard FBS or Exo-FBS supplement were analyzed, and ELISA signals were normalized to the standard FBS control.
Figure 3. qPCR analysis demonstrates the absence of detectable bovine exosomal miRNAs in Exo-FBS.
Quantitative PCR (qPCR) profiling of bovine exosomal microRNAs revealed that standard FBS contains amplifiable miRNAs, with 12 of 72 miRNAs detected (left panels), whereas Exo-FBS showed no detectable miRNA amplification (right panels). For analysis, 4 mL of standard FBS or Exo-FBS media supplement was processed using TRIzol-based RNA extraction to recover exosome-associated RNAs. Purified RNA was reverse-transcribed to cDNA, and 72 individual bovine miRNAs were quantified by qPCR using SBI’s QuantiMir™ system.